Ariad Pharmaceuticals (ARIA) collapses 59% after the company says that it's suspending the enrollment of new patients in trials for its Iclusig treatment for chronic myeloid leukemia.
The pause follows an increase in the rate of cardiac problems in patients who received Iclusig.
Pending FDA approval, Ariad hopes to resume enrollment with lower doses of the drug. Patients already on the medicine will continue to do so but with smaller doses.
The U.S. prescribing information for Iclusig remains unchanged. (PR)